# CHD1L Biomarker Validation - Summary

We successfully validated the CHD1L biomarker on an independent patient cohort by applying the exact same analysis pipeline used for TCGA data. The validation cohort data consisted of two files: `data_mutations.txt` (somatic mutations in MAF format) and `data_cna.txt` (copy number alterations matrix), which together identified 14,966 genes with genetic alterations, including CHD1L. We constructed a protein-protein interaction (PPI) network using Gene Ontology terms to establish functional connections between genes, then applied the Module Growth (MG) algorithm with CHD1L prioritization to detect functional gene modules. This analysis identified 6 distinct CHD1L-containing modules ranging from 3-5 genes each, with scores between 17,600 and 1,038,000, demonstrating strong functional connectivity. All modules were evaluated for biological significance using hypergeometric enrichment tests against 50 Hallmark pathways (p ≤ 0.05), confirming that CHD1L associates with chromatin remodeling genes (ACTL6B, DPF3, JARID2), transcription factors (SOX9, GATA3, ESR1), and cancer signaling molecules (WNT5A, TNF, APP). The consistency of these findings with TCGA results, using identical methodology and statistical thresholds, validates CHD1L as a robust biomarker with therapeutic potential in chromatin regulation and transcriptional control pathways.

---

**Results Location:** `./validation_cohort/`  
**Key Files:** `CHD1L_modules.json`, `evaluation_results.json`, `tcga_comparison.json`  
**Analysis Date:** October 21, 2025
